A Pharmacovigilance Study on the Safety of Axicabtagene Ciloleucel Based on Spontaneous Reports from the EudraVigilance Database
C Rafaniello, V Liguori, A Zinzi, M Gaio, A Falco… - Biomedicines, 2023 - mdpi.com
During pre-approval clinical trials, the safety of axi-cel, a second-generation CAR-T-cell
therapy directed against CD19, which dramatically improved the prognosis of intractable B …
therapy directed against CD19, which dramatically improved the prognosis of intractable B …
Viability variation of T-cells under ultrasound exposure according to adhesion condition with bubbles
N Kajita, Y Ito, S Watanabe, Y Miyamoto… - Journal of Medical …, 2023 - Springer
Purpose Although cellular immunotherapy is expected as a new cancer treatment, its
therapeutic efficiency is limited in solid tumors, because most cells return to the bloodstream …
therapeutic efficiency is limited in solid tumors, because most cells return to the bloodstream …
Chimeric antigen receptor T-cell immunotherapies adverse events reported to FAERS database: focus on cytopenias
A Gomez-Lumbreras, S Mercadal Vilchez… - Leukemia & …, 2023 - Taylor & Francis
Chimeric antigen receptor (CAR) T-cell therapy presents a promising treatment for
hematologic malignancies, displaying high efficacy but not being exempt from toxicity. In this …
hematologic malignancies, displaying high efficacy but not being exempt from toxicity. In this …
[HTML][HTML] 以B 细胞成熟抗原为基础的CAR-T 细胞治疗对复发/难治性多发性骨髓瘤患者肝功能影响的临床观察
孙乾， 祁岳坤， 齐昆明， 闫志凌， 程海… - Chinese Journal of …, 2023 - ncbi.nlm.nih.gov
以B细胞成熟抗原为基础的CAR-T细胞治疗对复发/难治性多发性骨髓瘤患者肝功能影响的临床观察
- PMC Back to Top Skip to main content NIH NLM Logo Access keys NCBI Homepage MyNCBI …
- PMC Back to Top Skip to main content NIH NLM Logo Access keys NCBI Homepage MyNCBI …
Pharmacovigilance and drug repositioning research using pharmacoepidemiology
Y Noguchi, M Yan, S Yokoyama… - Frontiers in Pharmacology, 2023 - frontiersin.org
Pharmacoepidemiology, the study of the use and effects of medicines in large human
populations, is a bridging science between clinical pharmacology and epidemiology …
populations, is a bridging science between clinical pharmacology and epidemiology …
CAR-T cells—Real-time experience applying CAR-T cells—What we have learned so far
H Greinix - memo-Magazine of European Medical Oncology, 2022 - Springer
CD19-targeted chimeric antigen receptor-engineered (CAR)-T cells are novel therapies
showing great promise for patients with relapsed or refractory diffuse large B cell lymphoma …
showing great promise for patients with relapsed or refractory diffuse large B cell lymphoma …
Quality Control Considerations Specific to the Development and Production of Gene and Cell Therapies
T Chand, AK Dubey - Quality Control and Regulatory Aspects for …, 2024 - taylorfrancis.com
The latest innovation in biopharmaceutical manufacturing is “cell and gene therapy”(CGT).
CGT is regulated as a drug or therapeutic product in India and other countries. These …
CGT is regulated as a drug or therapeutic product in India and other countries. These …
Infectious Complications Distribution Following CLL1 CAR-T Cell Therapy for Acute Myeloid Leukemia
J Xu, H Zhang, Y Zhao, X Zhang, S Guo, X Shi, X Xiao… - 2024 - researchsquare.com
The CLL1-targeted chimeric antigen receptor T (CAR-T) cell therapy offers a novel
therapeutic approach for refractory or relapsed acute myeloid leukemia (AML). The targeted …
therapeutic approach for refractory or relapsed acute myeloid leukemia (AML). The targeted …
Observation of liver indexes in patients with relapsed/refractory multiple myeloma treated with CAR-T-cells based on BCMA
Q Sun, YK Qi, KM Qi, ZL Yan, H Cheng… - Zhonghua xue ye xue …, 2023 - europepmc.org
Objective: To observe the characteristics of the evolution of liver indexes in patients with
relapsed/refractory multiple myeloma (RRMM) treated with CAR-T-cells based on BCMA …
relapsed/refractory multiple myeloma (RRMM) treated with CAR-T-cells based on BCMA …